NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD)

Completed · Phase 3 · Has a placebo group

Conditions studied: Attention Deficit Hyperactivity Disorder

In brief

The safety and efficacy of a chewable formulation of extended-release methylphenidate will be studied in children with ADHD

Key facts

Study ID

NCT01654250

Run by

Pfizer

People needed

90

Starts

2012-07-01

Expected to finish

2012-10-01

Last updated by the study team

2016-02-03

Who can join

Age: 6 and older, up to 12. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Children aged 6 to 12 years with ADHD who require pharmacologic treatment for this condition

You may not qualify if…

• Other serious illnesses or conditions that would put the patient at particular risk for safety events or would interfere with treatment/assessment of ADHD

Where it is running

• Clinical Study Centers, LLC — Little Rock, Arkansas, United States
• Laboratory School — Huntington Beach, California, United States
• UC Irvine Child Development Center — Irvine, California, United States
• UC Irvine - Hewitt Hall — Irvine, California, United States
• Florida Clinical Research Center, LLC — Bradenton, Florida, United States
• Woodland Community Church (Laboratory School) — Bradenton, Florida, United States
• Center for Psychiatry and Behavioral Medicine, Inc. — Las Vegas, Nevada, United States
• Bayou City Research, Ltd. — Houston, Texas, United States
• Westex Clinical Investigations — Lubbock, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.